Seroprevalence of neutralizing antibodies to measles virus in a vaccinated population in Iran, 1998

European Journal of Epidemiology

Volumn 18, Issue 11, 2003, Pages 1085-1089

  Loo, Mazaher Khodabandeh ^a   Sabahi, Farzaneh ^a   Soleimanjdahi, Horieh ^a   Kazemnejad, Anooshirvan ^a   Roustai, Mohammod Hassan ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Immunization; Measles; Microneutralization assay; Seroprevalence

Indexed keywords

MEASLES VACCINE; NEUTRALIZING ANTIBODY;

ADOLESCENT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; FEMALE; HELA CELL; HUMAN; HUMAN CELL; INFANT; INFECTION CONTROL; IRAN; MAJOR CLINICAL STUDY; MALE; MEASLES; MEASLES VACCINATION; MICRONEUTRALIZATION ASSAY; NONHUMAN; SEROPREVALENCE; VACCINATION; VIRUS INFECTION; VIRUS NEUTRALIZATION;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT; IRAN; MALE; MEASLES; MEASLES VACCINE; MEASLES VIRUS; SEROEPIDEMIOLOGIC STUDIES;

EID: 0242332639     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026104522780     Document Type: Article

References (21)

1. Cox MJ, Azevedo RS, Massad E, et al. Measles antibody level in a vaccinated population in Brazil. Trans R S Trop Med Hygiene 1998; 92: 227-230.
2. Grandolfo ME, Medda E, Novello F, et al. Seroepidemiological evaluation of 1989-1991 mass vaccination campaigns against measles in Italy. Epidemiol Infect 1998; 121: 645-652.
3. Aaby P, Knudsen K, Jensen TG, et al. Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage. J Infect Dis 1990; 162: 1043-1048.
4. Matter L, German D, Bally F, et al. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Eur J Epidemiol 1997; 13: 61-66.
5. Babad HR, Nokes DJ, Gay NJ, et al. Predicting the impact of measles vaccination in England and Wales: Mode 1 validation and analysis of policy options. Epidemiol Infect 1995; 114: 319-344.
6. Redd SC, Markowitz LE, Katz SL. Measles Vaccine. In: Plotkin and Orenstein's Vaccines, 3rd ed. Philadelphia: W.B. Saunders Company, 1999: 222-265.
7. Reports of epidemiological studies in Iran, years 1996, 1997 and 1998. National Institute for Prevention and Control of Diseases, Ministry of Health and Health Education of Iran.
8. Mokhtari-Azad T, Naghavi M, Hassan Negad Q, Nategh R. Assessment of immune status against measles in relation with vaccination history in children 7-11 years old in town of Ray in 1992. J Med School Tehran Univ 1994; 52(3-4): 41-49.
9. Lennette EH. Diagnosis Procedure for Viral, Rickettsial and Chlamydial Infections. 7th ed. Washington DC: American Public Health Association, 1995.
10. Ballew HC. Neutralization. In: Clinical Virology Manual, 2nd ed. New York: Elsevier, 1992; 229-242.
11. Kalter SS, Herberling RL, Barry JD, et al. Detection and titration of measles virus antibody by hemagglutination inhibition and by dot immunobinding. J Clin Microbiol 1991; 29(1): 202-204.
12. Neumann PW, Weber JM, Jessamine AG, et al. Comparison of measles antihemolysin test, enzyme-linked immunosorbent assay, and hemagglutination inhibition test with neutralization test for determination of immune status. J Clin Microbiol 1985; 22(2): 296-298.
13. Lee MS, et al. Seroepidemiology and evaluation of passive surveillance during 1988-1989 measles outbreak in Taiwan. Int J Epidemiol 1992; 21(6): 1165-1174.
14. Cutts FT, Lauri E, Markowitz E. Successes and failures in measles control. J Infect Dis 1994; 170(Suppl. 1): S32-41.
15. Daie Parizi MH, Janghorbani M, Ghorbani K. Measles epidemics in Kerman, Iran. Med J Islamic Republic Iran 1993; 6(4): 249-254.
16. Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants 6, 9, and 12 months. J Infect Dis 2001; 184: 817-826.
17. Hutchins SS, Redd SC, Schrag S, et al. Evaluation of an early two-dose 1 measles vaccination schedule. Am J Epidemiol 2001; 154: 1064-1071.
18. Bautista-Lopez N, Ward BJ, Mills E, et al. Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 2000; 18: 1393-1401.
19. Griffin DE, Ward BJ, Esolen LM, et al. Pathogenesis of measles virus infection: A hypothesis for altered immune response. J Infect Dis 1994; 170(1): 524-531.
20. Griffin DE, Bellini WJ. Measles Virus. In: Field's Virology, 3rd ed. New York: Raven Press, 1996; 1267-1313.
21. Lee MS, Cohen B, Hand J, Nokes J. A simplified and standardized neutralization enzyme immunoassay for the quantification of measles neutralizing antibody. J Virol Meth 1999; 78: 209-217.